Statin-induced myopathies
Pharmacological Reports, ISSN: 1734-1140, Vol: 63, Issue: 4, Page: 859-866
2011
- 196Citations
- 281Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations196
- Citation Indexes158
- 158
- CrossRef102
- Policy Citations37
- 37
- Clinical Citations1
- PubMed Guidelines1
- Captures281
- Readers281
- 281
- Mentions2
- Blog Mentions1
- Blog1
- News Mentions1
- 1
Most Recent News
Experts Warn About Myopathy Side Effect of Cholesterol-Lowering Drug, Simvastatin; Fluvastatin XL, Lower Risk
Photo bywww.rxlist.com A prospective cohort study conducted by the National Center for Diabetes, Endocrinology, and Genetics (NCDEG), Jordan, published in the Annals of Medicine and
Review Description
Statins are considered to be safe, well tolerated and the most efficient drugs for the treatment of hypercholesterolemia, one of the main risk factor for atherosclerosis, and therefore they are frequently prescribed medications. The most severe adverse effect of statins is myotoxicity, in the form of myopathy, myalgia, myositis or rhabdomyolysis. Clinical trials commonly define statin toxicity as myalgia or muscle weakness with creatine kinase (CK) levels greater than 10 times the normal upper limit. Rhabdomyolysis is the most severe adverse effect of statins, which may result in acute renal failure, disseminated intravascular coagulation and death. The exact pathophysiology of statin-induced myopathy is not fully known. Multiple pathophysiological mechanisms may contribute to statin myotoxicity. This review focuses on a number of them. The prevention of statin-related myopathy involves using the lowest statin dose required to achieve therapeutic goals and avoiding polytherapy with drugs known to increase systemic exposure and myopathy risk. Currently, the only effective treatment of statin-induced myopathy is the discontinuation of statin use in patients affected by muscle aches, pains and elevated CK levels.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1734114011706016; http://dx.doi.org/10.1016/s1734-1140(11)70601-6; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=80053373582&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/22001973; http://linkinghub.elsevier.com/retrieve/pii/S1734114011706016; http://api.elsevier.com/content/article/PII:S1734114011706016?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1734114011706016?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S1734114011706016; http://dx.doi.org/10.1016/s1734-1140%2811%2970601-6; https://dx.doi.org/10.1016/s1734-1140%2811%2970601-6
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know